At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 75 enrolled
Drug / intervention
Pegylated Interferon alfa-2b +1 morebiological
Likely dose
Ribavirin 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b in CHC Patients With genotype1 High Viral Load and Low Body Weight
In Brief
A Phase 4 clinical trial evaluating Pegylated Interferon alfa-2b and Ribavirin for Hepatitis C, Chronic. Completed, enrolled 75 participants.
Detailed Summary
The objective is to evaluate the efficacy and safety of the combination therapy with subcutaneous (SC) Pegylated Interferon (PEG-IFN) alfa-2b 1.5 ug/kg/week plus low-dose ribavirin administered for 48 weeks in participants with chronic hepatitis C virus (HCV) who are infected with HCV genotype 1 high viral load, and weigh 50 kg or less.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatitis C, Chronic
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedMay 2008
Primary CompletionDec 2010
TodayJul 2026
First PostedMay 30, 2008
Enrollment StartJan 1, 2008
Primary CompletionDec 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 18.1 years ago
Interventions
Pegylated Interferon alfa-2bbiological
Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
Ribavirindrug
Ribavirin 400 mg/day orally